Chronic autoimmune skin condition
120 matching trials — Updated daily from ClinicalTrials.gov
Psoriasis clinical trial monitoring is the process of systematically tracking new and updated clinical trials related to psoriasis on ClinicalTrials.gov, the world's largest registry of clinical studies maintained by the U.S. National Library of Medicine. TrialsAlert scans this database every day, using artificial intelligence to classify each trial by its potential impact on patients with psoriasis. Trials are scored across six dimensions including phase importance, breakthrough potential, and patient accessibility. Every Friday, subscribers receive a plain-language research briefing explaining which psoriasis trials were added or updated that week, what phase they are in, who is sponsoring them, and why they matter. This replaces the 5 or more hours per week that patients and caregivers typically spend manually searching for clinical trial updates for their condition.
This week, 42 clinical studies related to skin conditions were reported, including 19 notable and 2 advanced Phase 3 trials focused on psoriasis. Several important psoriasis studies have completed with results now available, especially those testing bimekizumab, a biologic treatment for moderate to severe chronic plaque psoriasis, involving hundreds of participants worldwide. Additionally, long-term safety studies of spesolimab for generalized pustular psoriasis continue, and new trials are recruiting to explore promising treatments like TRIV-509 and AK139 for atopic dermatitis, which often overlaps with psoriasis symptoms.
Among the most significant findings are multiple Phase 3 trials of bimekizumab, which have shown potential to improve skin clearance and disease control for adults with moderate to severe chronic plaque psoriasis. These studies suggest this treatment might offer better symptom relief compared to existing therapies, though final results and regulatory decisions will guide its future use. Another notable study is the ongoing long-term evaluation of spesolimab for generalized pustular psoriasis, a rare but severe form, which may help manage flares over several years. These Phase 2 and 3 trials indicate that new options are being carefully tested but are still several years away from routine availability.
Other research includes innovative approaches like personalized medicine using gene patterns to predict treatment response, studies on nail psoriasis treatments, and investigations into improving treatment adherence. Overall, the field is moving toward more targeted therapies and better understanding of individual responses, which could lead to more effective and tailored care in the future.
What this means for you is that while new treatments for psoriasis are actively being studied and some show promise, they are still under investigation and not yet widely available. It’s important to continue working closely with your healthcare provider to manage your condition with current approved therapies and to discuss any questions about emerging treatments or clinical trial participation.
Phase: PHASE4
This trial tests a biologic drug called guselkumab in people with psoriasis who are at high risk of developing psoriatic arthritis. If successful, it could help prevent or reduce joint inflammation and damage in these patients. The study is currently recruiting in North America and results are expected after two years of treatment.
Sponsored by NYU Langone Health | NCT05004727
Phase: PHASE3
This study evaluates the effectiveness and safety of zasocitinib in adults with active psoriatic arthritis who have not used biologic treatments before. Participants will receive either zasocitinib, an active comparator, or placebo and will be followed for up to 60 weeks. The goal is to improve joint and skin symptoms associated with psoriatic arthritis.
Sponsored by Takeda | NCT06671483
Phase: PHASE3
This study evaluates the safety and effectiveness of guselkumab, a biologic treatment, in children aged 6 to under 18 with chronic plaque psoriasis. The goal is to improve skin clearance and quality of life in pediatric patients. The trial compares guselkumab to placebo and etanercept across multiple countries.
Sponsored by Janssen Research & Development, LLC | NCT03451851
We scan ClinicalTrials.gov daily for psoriasis trials, classify each by potential impact using AI (breakthrough, notable, or routine), and deliver weekly research briefings explaining what changed and why it matters. Our matching system uses medical synonyms, related treatments, and disease domain classification to ensure you never miss a relevant trial.
Get a weekly briefing with the trials that matter most.